MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Analysis of the olfactory impairments in PINK1 deficient mice

    A. Hummel, A. Zimprich, L. Garret, B. Sperling, F. Giesert, J. Nagler, H. Fuchs, V. Gailus-Durner, M. Hrabé de Angelis, S.M. Koch, D. Vogt Weisenhorn, W. Wurst (Neuherberg, Germany)

  • Anhedonia and its correlation with clinical aspects in Parkinson’s disease

    H. Nagayama (Tokyo, Japan)

  • Anosmia predicts development of more severe motor symptoms including freezing of gait and impaired balance at 2 year follow-up in PD

    N.I. Bohnen, J. Haugen, V. Kotagal, K.A. Frey, R.L. Albin, M.L.T.M. Muller (Ann Arbor, MI, USA)

  • Anti-GAD antibody cerebellar ataxia mimicking multiple system atrophy

    J.B. Parmera, L.S.V. Schneider, R.G. Cury, M.M. Simabukuro, L.H.M. Castro, E.R. Barbosa (São Paulo, Brazil)

  • Anti-LGI1 encephalitis presenting as a progressive supranuclear palsy-like syndrome

    G.A. Da Prat, E.M. Gatto, G.G. Persi, V. Parisi, D. Lisei, L. Rattagan, M. Bres Bullrich, S. Camerlingo, C. Rugilo, M. Titulaer, G. Rojas (Caba, Argentina)

  • AntiParkinsonian effects of AG-0029 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

    E.Y. Pioli, W.K.D. Ko, Q. Li, A. Crossman, E. Bezard, S. Hogg (Manchester, United Kingdom)

  • AntiParkinsonian effects of the “radiprodil and tozadenant” combination in MPTP-treated marmosets

    A. Michel, J.M. Nicolas, S. Rose, M. Jackson, P. Colman, W. Briône, D. Sciberras, P. Muglia, D. Scheller, M. Citron, P. Downey (Braine L'Alleud, Belgium)

  • AntiParkinsonian medication adjustments following deep brain stimulation of subthalamic nucleus in patients with advanced Parkinson’s disease

    A. Gamaleya, E. Bril, A. Tomskiy, A. Poddubskaya, N. Gubareva, N. Fedorova, V. Shabalov (Moscow, Russia)

  • AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia

    L. Kadastik-Eerme, N. Taba, P. Taba (Tartu, Estonia)

  • Anxiety and cognition are associated with dopaminergic dysfunction in de novo Parkinson’s disease

    M. Picillo, G. Santangelo, R. Erro, A. Cozzolino, M. Amboni, C. Vitale, P. Barone, M.T. Pellecchia (Baronissi, Italy)

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 207
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley